Sebetralstat (KVD900) for Hereditary Angioedema Prophylaxis
This study is testing a drug called sebetralstat (KVD900) to see how safe and effective it is at preventing swelling attacks in people with Hereditary Angioedema (HAE) before they have medical procedures. HAE is a rare genetic condition that causes episodes of severe swelling. The study aims to see how many procedures don't lead to an HAE attack within 24 hours after the procedure starts when sebetralstat is used. You may be able to join if you are 12 years or older, have a confirmed diagnosis of HAE Type I or II, and have a procedure scheduled soon. The study is currently recruiting about 100 participants, but its overall status is unclear.
- Study design
- This is a Phase 4, open-label study, meaning both you and your doctors will know you are receiving sebetralstat. It plans to enroll about 100 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main measurement for the study is taken 24 hours after your procedure begins.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Study Director · STUDY_DIRECTOR · KalVista Pharmaceuticals, Ltd.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- The number and proportion of STPs that did not result in an HAE attack within 24 hours after the start of the procedure will be summarized.24 hours following the start of the procedure